Clinical Trial Update: Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating brentuximab vedotin with or without nivolumab in patients with relapsed or refractory CD30-positive Hodgkin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• OPDIVO (nivolumab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING